Q1 EPS Estimates for MiMedx Group Raised by Northland Capmk

MiMedx Group, Inc. (NASDAQ:MDXG) – Research analysts at Northland Capmk raised their Q1 2025 EPS estimates for MiMedx Group in a report released on Thursday, February 27th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings per share of $0.06 for the quarter, up from their previous forecast of $0.05. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group’s Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.08 EPS and FY2026 earnings at $0.38 EPS.

A number of other analysts have also recently weighed in on MDXG. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price objective on shares of MiMedx Group in a report on Thursday. StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $12.40.

MiMedx Group Price Performance

Shares of NASDAQ MDXG opened at $8.40 on Friday. The stock’s 50-day simple moving average is $8.72 and its 200-day simple moving average is $7.70. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The firm has a market capitalization of $1.23 billion, a PE ratio of 15.27 and a beta of 1.94. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.07. The company had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%.

Institutional Investors Weigh In On MiMedx Group

Several large investors have recently modified their holdings of the company. Blue Trust Inc. purchased a new stake in MiMedx Group in the 3rd quarter valued at $30,000. Allspring Global Investments Holdings LLC increased its stake in MiMedx Group by 1.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 183,021 shares of the company’s stock valued at $1,082,000 after purchasing an additional 1,822 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of MiMedx Group by 88.6% in the third quarter. Farther Finance Advisors LLC now owns 24,599 shares of the company’s stock valued at $145,000 after buying an additional 11,557 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of MiMedx Group by 299.9% during the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock worth $6,074,000 after buying an additional 770,744 shares during the period. Finally, Cannon Global Investment Management LLC grew its holdings in shares of MiMedx Group by 47.1% during the third quarter. Cannon Global Investment Management LLC now owns 25,000 shares of the company’s stock worth $148,000 after buying an additional 8,000 shares during the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.